Observational, feasibility study investigating biological aspects in patients with liver metastasis from colorectal cancer undergoing treatment with SIRT, by translational analysis of biological samples.
Diagnosis of metastatic colorectal adenocarcinoma with liver dominant disease
Diagnosis of liver metastasis may be made by histo- or cyto-pathology, or by clinical and imaging criteria.
The Liver metastasis are not eligible for resection, RFA or SBRT
All patients must be off all chemotherapeutic regimens for 14 days prior to SIRT treatment
Pretherapeutic work-up procedure with Tc-99m macroaggregated albumin (MAA) scintigraphy showing extrahepatic foci in GI-tract
Evidence of any detectable Tc-99m macroaggregated albumin deposition in the stomach or duodenum, after application of established angiographic techniques to stop such deposition
Previous radiation therapy to the lungs and/or to the upper abdomen overlapping with dose to the liver at interventionist´s decision
Lung shunt greater than 20% or > 30 Gray radiation absorbed dose to the lungs, at estimated by Tc-99m-MAA
The study population consists of patients with metastatic colorectal cancer with chemorefractory liver dominant disease. Patients are found not eligible for surgical resection, RFA or SBRT by a multidisciplinary tumour board (MDT), and considered candidates for SIRT treatment in order to obtain disease control or resectability.
Case-only
Prospective
Not listed
Feasibility and translational analysis
Investigating potential prognostic and predictive markers for efficacy by molecular characteristics and mutational analysis
Response Rate
According to RECIST 1.1
Progression Free Survival
Overall Survival
Click on the lead sponsor to view all of their trials.
